All In MedTech

Device Trial Radar · NCT00788671

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

69

Actual

Start

Nov 3, 2008

Primary completion

Jun 10, 2016

Study completion Nov 30, 2027

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 11, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer. High levels of estrogen can cause the growth of endometrial cancer cells. Progesterone can help balance the amount of estrogen present. Hormone therapy using levonorgestrel, a type of progesterone, may fight endometrial cancer by helping regulate hormone levels.

Conditions

  • Atypical Endometrial Hyperplasia
  • Stage I Uterine Corpus Cancer AJCC v7
  • Stage IA Uterine Corpus Cancer AJCC v7
  • Stage IB Uterine Corpus Cancer AJCC v7
  • Stage II Uterine Corpus Cancer AJCC v7

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Levonorgestrel-Releasing Intrauterine SystemDevice

    Undergo placement of a levonorgestrel-releasing intrauterine system

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate at 12 MonthTime frame: At 1 year
  2. Efficacy of the Levonorgestrel Intrauterine Device (IUD)Time frame: At 1 year

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Lyndon Baines Johnson General Hospital

    Houston, Texas

  • M D Anderson Cancer Center

    Houston, Texas

  • The Woman's Hospital of Texas

    Houston, Texas

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.